Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Dow
QuintilesIMS
Deloitte
Cantor Fitzgerald
Cipla
US Army
McKesson
Argus Health
AstraZeneca

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021928

« Back to Dashboard

NDA 021928 describes CHANTIX, which is a drug marketed by Pfizer Inc and is included in one NDA. It is available from nine suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the CHANTIX profile page.

The generic ingredient in CHANTIX is varenicline tartrate. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
Summary for 021928
Tradename:CHANTIX
Applicant:Pfizer Inc
Ingredient:varenicline tartrate
Patents:3
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021928
Medical Subject Heading (MeSH) Categories for 021928
Suppliers and Packaging for NDA: 021928
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Pfizer Laboratories Div Pfizer Inc 0069-0468 0069-0468-56 56 TABLET, FILM COATED in 1 BOTTLE (0069-0468-56)
CHANTIX varenicline tartrate TABLET;ORAL 021928 NDA Pfizer Laboratories Div Pfizer Inc 0069-0469 0069-0469-03 1 BLISTER PACK in 1 CARTON (0069-0469-03) > 56 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 0.5MG BASE
Approval Date:May 10, 2006TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 12, 2019
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Dec 16, 2019
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Oct 15, 2017
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Teva
Cipla
Citi
Dow
Accenture
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot